Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
| 14.25 | |
| 14.25 | |
| - | |
| 14.25 | |
| 14.25 | |
| 6.17-17.205 | |
| 1 853 M | |
| 17.8125 | |
| 130 M | |
| 232 M | |
| 2.155 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The Australian market has shown robust growth, climbing 3.0% in the past week and achieving a 10% increase over the last twelve months, with earnings projected to grow by 14% per annum. In this contex...
The Australian market has shown robust performance, rising 2.1% over the last week and achieving a 10% increase over the past year with earnings expected to grow by 13% annually. In this context, iden...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
